Answers are grounded in this paper and cite their sources.
Evaluation of pharmacogenomics and functional imaging in predicting sunitinib response and toxicity, indicating associations with progression-free survival.
Aim Sunitinib has marked pharmacokinetic (PK) and pharmacodynamic (PD) interpatient variability. This study evaluated the utility of extensive excretory/metabolic/PD pharmacogenomics (PGx) with hepatic functional imaging (HNI) to explore their associations with sunitinib PK/PD (toxicity/response) and progression‐free survival (PFS), respectively. Methods Eligible patients (pts) suitable for sunitinib therapy. At baseline: (i) PGx: blood analysed by the Affymetrix DMET™ Plus Array (1936 variants/225 genes) and Sanger sequencing (HNF1A, FLT3, VEGFR2, VEGFR3, RET, PDGFRα, TNFα). (ii) HNI: pts given IV 800 MBq 99m Tc‐MIBI, imaging data analysed for hepatic extraction/excretion parameters (CL HNI , T 1/2‐HNI , 1hRET, HEF, T d1/2 ). In cycles 1 and 2, bloods taken for sunitinib parent (SU), metabolite (SU12662) and total SU (metabolite + parent) PK. Associations evaluated between (i) HNI parameters and (2) PGx, with sunitinib PK, toxicity/response and PFS. Results N = 15 pts. The two most significant associations in either direction between PGx variants or HNI parameters ( p < .05) for: (i) PK included: (a) SU logAUC 0–14days with HEF, ATP7B (rs1801246) and UGT8 (rs4148254); (b) SU logAUC 0–28days , with T d1/2 , SLC15A1 (rs8187832) and SLC10A2 (rs188096); (c) SU12662 logAUC 0–14days with HEF, ABCC3 (rs11568591), PPARD (rs1003973) and SLC15A1 (rs8187840); and (d) SU12662 logAUC 0–28days with SULT1A2 (rs1059491) and SLC10A2 (rs188096). (ii) Toxicity: (a) Diarrhoea grade 1+ with HEF, VEFGR3 (rs307826) and AKAP9 (rs7785971); (b) ≥grade 3 AEs with CBR1 (rs998383); (iii) overall response rate with SULT1E1 (rs1881668) and GSTA2 (rs2180314); and (iv) PFS with CYP4Z1 (rs4926802) and CYP2A6 (rs28399442). Conclusions Exploratory associations were observed between sunitinib PK/PD with hepatic functional imaging with extensive pharmacogenomics. Further validation is required.
No takes yet. Share an insight, caveat, or question.
Michael et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: